Modulatory effects of sCD14 and LBP on LPS-host cell interactions
Open Access
- 1 August 2005
- journal article
- other
- Published by SAGE Publications in Innate Immunity
- Vol. 11 (4) , 225-229
- https://doi.org/10.1177/09680519050110040701
Abstract
LPS binding protein (LBP) and CD14 play key roles in promoting innate immunity to Gram-negative bacteria by transferring LPS to the signaling receptor complex, MD-2/Toll-like receptor 4 (TLR4). LBP and soluble CD14 (sCD14) can also inhibit responses to LPS by mechanisms that depend on their concentration and environment; during acute inflammation and infection, their concentrations increase in plasma and extravascular fluids. Whereas low concentrations of LBP enhance responses to LPS, high LBP concentrations can inhibit LPS bioactivity in vitro and in vivo. sCD14 also inhibits cell responses by diverting LPS from membrane-bound CD14 (mCD14) and by promoting LPS efflux from cell-surface mCD14 and transferring it to plasma lipoproteins. In vivo studies support the hypothesis that sCD14 has systemic anti-inflammatory effects, whereas in the tissues it may have pro-inflammatory effects that increase resistance to bacteria. Likewise, LBP increases resistance to Gram-negative bacteria by rapidly triggering pro-inflammatory responses to LPS. Thus, the dual stimulatory and inhibitory mechanisms of sCD14 and LBP may benefit the infected host by promoting inflammation in local sites, where it is needed, while at the same time preventing potentially detrimental systemic responses to LPS.Keywords
This publication has 43 references indexed in Scilit:
- LPS-binding protein-deficient mice have an impaired defense against Gram-negative but not Gram-positive pneumoniaInternational Immunology, 2004
- Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteinsJournal of Lipid Research, 2003
- Regulation of interactions of endotoxin with host cellsInnate Immunity, 2003
- The dual role of LBP and CD14 in response to Gram-negative bacteria or Gram-negative compoundsInnate Immunity, 2003
- Recombinant Soluble CD14 Reduces Severity of Intramammary Infection byEscherichia coliInfection and Immunity, 2003
- Lipopolysaccharide-Binding Protein and Phospholipid Transfer Protein Release Lipopolysaccharides from Gram-Negative Bacterial MembranesInfection and Immunity, 2000
- LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria.Journal of Clinical Investigation, 1998
- Increased Serum Concentration of Soluble CD14 Is a Prognostic Marker in Gram-Positive SepsisClinical Immunology and Immunopathology, 1996
- Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14.The Journal of Experimental Medicine, 1994
- The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans.Journal of Clinical Investigation, 1990